Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1972;46(3):371–385.

BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life

Fourth Report to the Medical Research Council by its Tuberculosis Vaccines Clinical Trials Committee
PMCID: PMC2480749  PMID: 4537855

Abstract

This paper reports the 15-year results of a controlled clinical trial of BCG and vole bacillus vaccines in the prevention of TB. Among 54 239 participants, 583 cases of TB developed, of which 70% were of pulmonary TB and 15% of tuberculous pleural effusion without evidence of pulmonary TB. The annual incidence (per 1 000) of TB was 0.28 among the 13 598 BCG-vaccinated participants and 1.28 among the tuberculin-negative unvaccinated participants admitted concurrently (a 78% reduction); for vole bacillus vaccine (5 817 participants) the figures were 0.29 and 1.50 (an 81% reduction). Protection extended to all forms of TB (in particular, 10 cases of tuberculous meningitis or miliary pulmonary TB developed in unvaccinated, and none in vaccinated, participants) and was similar in the two sexes. It decreased gradually during the period but was still substantial (59% for BCG vaccine and 73% for vole bacillus vaccine) 10-15 years after vaccination; no definite conclusion can yet be reached on the level of protection after 15 years. The annual incidence of TB in those with strong positive reactions to tuberculin on entry was particularly high (3.75) in the first 2.5 years, reflecting active infections acquired before entry; those with weaker positive reactions on entry had a lower incidence throughout than the tuberculin-negative unvaccinated group, indicating that a degree of naturally acquired immunity (though less than that conferred by vaccination) was associated with the low-grade tuberculin sensitivity. The incidence of every form of TB decreased steeply during the 15 years, except for genito-urinary TB of which there were 3, 5, and 14 cases in successive 5-year periods, principally among initially tuberculin-positive participants. This report also presents the findings with respect to nontuberculous diseases, discusses the place of vole bacillus vaccination, and describes a method for assessing the applicability of mass BCG vaccination in a given epidemiological situation.

Full text

PDF
371

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARONSON J. D., ARONSON C. F., TAYLOR H. C. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. AMA Arch Intern Med. 1958 May;101(5):881–893. doi: 10.1001/archinte.1958.00260170037006. [DOI] [PubMed] [Google Scholar]
  2. Comstock G. W. Leukaemia and B.C.G. A controlled trial. Lancet. 1971 Nov 13;2(7733):1062–1063. doi: 10.1016/s0140-6736(71)90381-3. [DOI] [PubMed] [Google Scholar]
  3. Comstock G. W., Palmer C. E. Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis. 1966 Feb;93(2):171–183. doi: 10.1164/arrd.1966.93.2.171. [DOI] [PubMed] [Google Scholar]
  4. Comstock G. W., Webster R. G. Tuberculosis studies in Muscogee County, Georgia. VII. A twenty-year evaluation of BCG vaccination in a school population. Am Rev Respir Dis. 1969 Dec;100(6):839–845. doi: 10.1164/arrd.1969.100.6.839. [DOI] [PubMed] [Google Scholar]
  5. Comstock George W., Shaw Lawrence W. Controlled trial of BCG vaccination in a school population: Tuberculosis studies in Muscogee County, Ga. Public Health Rep. 1960 Jul;75(7):583–594. [PMC free article] [PubMed] [Google Scholar]
  6. DUBOS R. ACQUIRED IMMUNITY TO TUBERCULOSIS. Am Rev Respir Dis. 1964 Oct;90:505–515. doi: 10.1164/arrd.1964.90.4.505. [DOI] [PubMed] [Google Scholar]
  7. Davignon L., Lemonde P., St-Pierre J., Frappier A. B.C.G. vaccination and leukaemia mortality. Lancet. 1971 Jan 9;1(7689):80–81. doi: 10.1016/s0140-6736(71)90804-x. [DOI] [PubMed] [Google Scholar]
  8. Davignon L., Robillard P., Lemonde P., Frappier A. B.C.G. vaccination and leukemia mortality. Lancet. 1970 Sep 26;2(7674):638–638. doi: 10.1016/s0140-6736(70)91402-9. [DOI] [PubMed] [Google Scholar]
  9. Edwards L. B., Palmer C. E. Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci. 1968 Sep 5;154(1):140–148. doi: 10.1111/j.1749-6632.1968.tb16704.x. [DOI] [PubMed] [Google Scholar]
  10. HART P. D., MILLER C. L., SUTHERLAND I., LESSLIE I. W. Sensitivity to avian and human old tuberculin in man in Great Britain. Tubercle. 1962 Sep;43:268–286. doi: 10.1016/s0041-3879(62)80067-1. [DOI] [PubMed] [Google Scholar]
  11. HART P. D., SUTHERLAND I. ACQUIRED IMMUNITY TO TUBERCULOSIS. Am Rev Respir Dis. 1965 Jun;91:939–939. doi: 10.1164/arrd.1965.91.6.939. [DOI] [PubMed] [Google Scholar]
  12. Hart P. D. Efficacy and applicability of mass B. C.G. vaccination in tuberculosis control. Br Med J. 1967 Mar 11;1(5540):587–592. doi: 10.1136/bmj.1.5540.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mathé G., Schwarzenberg L., Amiel J. L., Schneider M., Cattan A., Schlumberger J. R., Tubiana M., Lalanne C. Immunogenetic and immunological problems of allogeneic haemopoietic radio-chimaeras in man. Scand J Haematol. 1967;4(3):193–216. doi: 10.1111/j.1600-0609.1967.tb01621.x. [DOI] [PubMed] [Google Scholar]
  14. PALMER C. E., SHAW L. W., COMSTOCK G. W. Community trials of BCG vaccination. Am Rev Tuberc. 1958 Jun;77(6):877–907. doi: 10.1164/artpd.1958.77.6.877. [DOI] [PubMed] [Google Scholar]
  15. Palmer C. E., Long M. W. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis. 1966 Oct;94(4):553–568. doi: 10.1164/arrd.1966.94.4.553. [DOI] [PubMed] [Google Scholar]
  16. ROSENTHAL S. R., LOEWINSOHNE, GRAHAM M. L., LIVERIGHT D., THORNE G., JOHNSON V. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics. 1961 Oct;28:622–641. [PubMed] [Google Scholar]
  17. STEIN S. C., ARONSON J. D. The occurrence of pulmonary lesions in BCG-vaccinated and unvaccinated persons. Am Rev Tuberc. 1953 Nov;68(5):695–712. doi: 10.1164/art.1953.68.5.695. [DOI] [PubMed] [Google Scholar]
  18. SUTHERLAND I., MILLER C. L., HART P. D. FURTHER STUDIES OF SENSITIVITY TO AVIAN AND HUMAN OLD TUBERCULIN IN MAN. Tubercle. 1964 Jun;45:110–113. doi: 10.1016/s0041-3879(64)80068-4. [DOI] [PubMed] [Google Scholar]
  19. SUTHERLAND I., MITCHELL D. N., HART P. D. INCIDENCE OF INTRATHORACIC SARCOIDOSIS AMONG YOUNG ADULTS PARTICIPATING IN A TRIAL OF TUBERCULOSIS VACCINES. Br Med J. 1965 Aug 28;2(5460):497–503. doi: 10.1136/bmj.2.5460.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Springett V. H., Sutherland I. Comparison of the efficacy of liquid and freeze-dried strains of B.C.G. vaccine in preventing tuberculosis. Br Med J. 1970 Oct 17;4(5728):148–150. doi: 10.1136/bmj.4.5728.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. WILLIS H. S., VANDIVIERE H. M., VANDIVIERE M. R., MELVIN I. Studies in tuberculo-immunity. Am J Med Sci. 1960 Aug;240:137–158. [PubMed] [Google Scholar]
  22. WILLIS S., VANDIVIERE M. The heterogeneity of BCG. Am Rev Respir Dis. 1961 Aug;84:288–290. doi: 10.1164/arrd.1961.84.2.288. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES